Urokinase

Urokinase

Clinical data
ATC code	B01AD04 (WHO)
Identifiers
IUPAC name Human urokinase
CAS Number	9039-53-6
DrugBank	BTD00030
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C1376H2145N383O406S18
Molar mass	31126.5 g/mol

plasminogen activator, urokinase
Identifiers
Symbol	PLAU
Entrez	5328
HUGO	9052
OMIM	191840
RefSeq	NM_002658
UniProt	P00749
Other data
EC number	3.4.21.31
Locus	Chr. 10 q24

WikiDoc Resources for Urokinase
Articles
Most recent articles on Urokinase Most cited articles on Urokinase Review articles on Urokinase Articles on Urokinase in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Urokinase Images of Urokinase Photos of Urokinase Podcasts & MP3s on Urokinase Videos on Urokinase
Evidence Based Medicine
Cochrane Collaboration on Urokinase Bandolier on Urokinase TRIP on Urokinase
Clinical Trials
Ongoing Trials on Urokinase at Clinical Trials.gov Trial results on Urokinase Clinical Trials on Urokinase at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Urokinase NICE Guidance on Urokinase NHS PRODIGY Guidance FDA on Urokinase CDC on Urokinase
Books
Books on Urokinase
News
Urokinase in the news Be alerted to news on Urokinase News trends on Urokinase
Commentary
Blogs on Urokinase
Definitions
Definitions of Urokinase
Patient Resources / Community
Patient resources on Urokinase Discussion groups on Urokinase Patient Handouts on Urokinase Directions to Hospitals Treating Urokinase Risk calculators and risk factors for Urokinase
Healthcare Provider Resources
Symptoms of Urokinase Causes & Risk Factors for Urokinase Diagnostic studies for Urokinase Treatment of Urokinase
Continuing Medical Education (CME)
CME Programs on Urokinase
International
Urokinase en Espanol Urokinase en Francais
Business
Urokinase in the Marketplace Patents on Urokinase
Experimental / Informatics
List of terms related to Urokinase

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Urokinase (Abbokinase), also called urokinase-type Plasminogen Activator (uPA), is a serine protease (EC 3.4.21.73). Urokinase was originally isolated from human urine, but is present in several physiological locations, such as blood stream and the extracellular matrix. The primary physiological substrate is plasminogen, which is an inactive zymogen form of the serine protease plasmin. Activation of plasmin triggers a proteolysis cascade which, depending on the physiological environment participate in thrombolysis or extracellular matrix degradation. This links urokinase to vascular diseases and cancer.

Molecular characteristics

Urokinase is a 411 residue protein, consisting of three domains: the serine protease domain, the kringle domain and the growth factor domain. Urokinase is synthesized as a zymogen form (prourokinase or single chain urokinase), and is activated by proteolytic cleavage between L158 and I159. The two resulting chains are kept together by a disulfide bond.

Interaction partners

The most important inhibitors of urokinase are the serpins plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2), which inhibits the protease activity irreversibly. In the extracellular matrix urokinase is tethered to the cell membrane by its interaction to the urokinase receptor.

• 
  Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.

Urokinase and cancer

Elevated expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated with tumor malignancy. It is believed that the tissue degradation following plasminogen activation, facilitates tissue invasion and thus contributes to metastasis. This makes urokinase an attractive drug target and inhibitors have been sought to be used as anticancer agents. However incompatibilities between the human and murine system hampers clinical evaluation of these agents. Through its interaction with the urokinase receptor, urokinase affects several other aspects of cancer biology such as cells adhesion, migration and cellular mitotic pathways.

Clinical applications

Urokinase is used clinically as a thrombolytic agent in the treatment of severe or massive deep venous thrombosis, pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis cannulas. Recently, Alteplase has replaced urokinase as a thrombolytic drug in acute infarction.

Template:WikiDoc Sources